Osteoporosis management program decreases incidence of hip fracture in patients with prostate cancer receiving androgen deprivation therapy

Urology

Volumn 81, Issue 5, 2013, Pages 1010-1017

  Zhumkhawala, Ali Asghar ^a   Gleason, Joseph M ^a   Craig Cheetham, T ^b   Niu, Fang ^b   Loo, Ronald K ^c   Dell, Richard M ^c   Jacobsen, Steven J ^c   Chien, Gary W ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b Pharmacy Analytical Service   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUPRORELIN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRAGILITY FRACTURE; HEALTH PROGRAM; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SCREENING;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; CALIFORNIA; FOLLOW-UP STUDIES; HIP FRACTURES; HUMANS; INCIDENCE; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84876693717     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2012.11.066     Document Type: Article

References (16)

1. M.R. Smith, R.A. Morton, and K.G. Barnette Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer J Urol 184 2010 1316 1321
2. A. SerpaNeto, M. Tobias-Machado, and M.A. Esteves A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma BMC Urol 10 2010 9
3. S.S. Rao, N. Budhwar, and A. Ashfaque Osteoporosis in men Am Fam Physician 82 2010 503 508
4. J. Morote, J.P. Morin, and A. Orsola Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer Urology 69 2007 500 504
5. L.J. Melton III, M.M. Lieber, and E.J. Atkinson Fracture risk in men with prostate cancer: a population-based study J Bone Miner Res 26 2011 1808 1815
6. L.S. Van Tongeren, G.G. Duncan, and D.L. Kendler Implementation of osteoporosis screening guidelines in prostate cancer patients on androgen ablation J Clin Densitom 12 2009 287 291
7. K. Ito, E.B. Elkin, M. Girotra, and M.J. Morris Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer Ann Intern Med 152 2010 621 629
8. National Osteoporosis Foundation Clinician's Guide to Prevention and Treatment of Osteoporosis Washington DC: National Osteoporosis Foundation 2010
9. P. Rosenbaum, and D. Rubin The central role of the propensity score in observational studies for causal effects Biometrika 70 1983 41 55
10. R.B. D'Agostino Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 1998 2265 2281
11. S.M. Perkins, W. Tu, and M.G. Underhill The use of propensity scores in pharmacoepidemiologic research Pharmacoepidmiol Drug Saf 9 2000 93 101
12. L.E. Braitman, and P.R. Rosenbaum Rare outcomes, common treatments: analytic strategies using propensity scores Ann Intern Med 137 2002 693 695
13. R.M. Dell, D. Greene, D. Anderson, and K. Williams Osteoporosis disease management: what every orthopaedic surgeon should know J Bone Joint Surg Am 6 91 suppl 2009 79 86
14. M. Smith Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma Cancer 97 3 suppl 2003 789 795
15. M.R. Smith, F. Saad, and B. Egerdie Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer J Urol 182 2009 2670 2676
16. P.J. Saylor, D.S. Kaufman, and M.D. Michaelson Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer J Urol 183 2010 2200 2205